Stock Comparison

BEAM vs JNJ

Beam Therapeutics Inc vs Johnson & Johnson

The Verdict

BEAM takes this one.

Winner

BEAM

Beam Therapeutics Inc

9.4

out of 10

Hidden Gem

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$3.2B

Market Cap

$557.1B

-5.2

P/E Ratio

26.5

-39.7%

Profit Margin

21.8%

-5.9%

Return on Equity

26.3%

0.2

Debt-to-Equity

0.6

Aggressive

Overall Risk

Conservative

9.4

DVR Score

1.0

The Deep Dive

BEAM9.4/10

Beam Therapeutics retains exceptionally high 10x growth potential, driven by its proprietary base editing platform, which continues to promise precision genetic cures. The recent Q1 2026 earnings report (May 7, 2026) provided critical clarity, showing a robust cash position of $1.2B against only $100M in debt, significantly de-risking financial runway concerns. Revenue surged +323% YoY, and EPS im...

Full BEAM Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.